Ottimizzare le prestazioni nell’ispezione visiva automatica con un ecosistema digitale
1 minute read
Abstract
Join this webinar to explore how pharma companies can navigate the evolving regulatory landscape and harness the full potential of AI technologies while staying ahead of FDA's cautious, risk-based approach to regulation.
New AI technologies hold tremendous potential for use in all areas of the pharma industry, but as the industry ventures into this uncharted territory, new regulatory considerations must be addressed. FDA Commissioner Robert Califf has communicated a desire to get ahead of regulating new disruptive technology and most anticipate that regulators will adopt a cautious yet risk-based approach. Alessandro Zannini, Director of Proposal and Product Management in Stevanato Group and Federico Scattolin, System Owner AI in Stevanato Group, will explore how pharma companies can navigate this evolving regulatory landscape in order to make the most of AI technologies.
Pharma Manufacturing - Stevanato Group
▶
WATCH THE WEBINAR
Pharma Manufacturing - Stevanato Group
▶
WATCH THE WEBINAR
WEBINAR
SU RICHIESTA
AI's Potential in Pharma Manufacturing
43 MIN.
ENGLISH
AI's Potential in Pharma Manufacturing
43 MIN.
ENGLISH
Stevanato Group
Stevanato Group è leader globale nella fornitura di soluzioni che spaziano dalla diagnostica al contenimento e alla somministrazione dei farmaci per i settori farmaceutico, biotecnologico e life science. Stevanato Group vanta un portafoglio integrato e completo di prodotti, processi e servizi che rispondono alle esigenze dei clienti attraverso l’intero ciclo di vita del farmaco dalle fasi di sviluppo, a quella clinica e commerciale.